Analysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Regeneron (REGN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Coherus Biosciences (CHRS – Research Report) and Regeneron (REGN – Research Report) with bullish sentiments.

Coherus Biosciences (CHRS)

In a report released yesterday, Yigal Nochomovitz from Citi maintained a Buy rating on Coherus Biosciences, with a price target of $11.00. The company’s shares closed last Wednesday at $2.69, close to its 52-week low of $1.43.

According to TipRanks.com, Nochomovitz is a 5-star analyst with an average return of 10.3% and a 46.3% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Lexicon Pharmaceuticals, and Apellis Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coherus Biosciences with a $11.57 average price target, implying a 285.7% upside from current levels. In a report issued on December 26, Robert W. Baird also reiterated a Buy rating on the stock with a $11.00 price target.

See the top stocks recommended by analysts >>

Regeneron (REGN)

In a report released yesterday, Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron. The company’s shares closed last Wednesday at $874.37, close to its 52-week high of $887.94.

According to TipRanks.com, Schott is a 3-star analyst with an average return of 1.6% and a 53.3% success rate. Schott covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Idexx Laboratories, and Gilead Sciences.

Regeneron has an analyst consensus of Strong Buy, with a price target consensus of $937.50, representing a 10.6% upside. In a report issued on December 12, Morgan Stanley also maintained a Buy rating on the stock with a $941.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CHRS:

• Coherus approval adds to 2024 growth outlook, says Barclays
• Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
• Coherus Biosciences announces FDA approval of UDENYCA ONBODY
• Coherus BioSciences Announces New Employment Inducement Grants
• Coherus Biosciences announces updated NCCN practice guidelines for LOQTORZI